Description: Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its workforce has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.
Home Page: www.aligos.com
ALGS Technical Analysis
One Corporate Drive
South San Francisco,
CA
94080
United States
Phone:
800 466 6059
Officers
| Name | Title |
|---|---|
| Dr. Lawrence M. Blatt MBA, Ph.D. | CEO & Chairman |
| Dr. Leonid Beigelman Ph.D. | Pres & Director |
| Dr. Julian A. Symons DPHIL | Exec. VP & Chief Scientific Officer |
| Ms. Lesley Ann Calhoun CPA | Exec. VP & CFO |
| Ms. Lucinda Y. Quan J.D. | Exec. VP, Chief Bus. Officer & Gen. Counsel |
| Kristina Engeseth | Exec. Director and Head of People & Culture |
| Mr. John Fry | Exec. VP of Clinical Devel. |
| Dr. Matthew W. McClure M.D. | Exec. VP & Chief Medical Officer |
| Dr. Sushmita M. Chanda DABT, Ph.D. | Exec. VP of Translational Safety Sciences |
| Dr. David B. Smith Ph.D. | Exec. VP & Head of Chemical Operations |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.3509 |
| Price-to-Sales TTM: | 3.7883 |
| IPO Date: | 2020-10-16 |
| Fiscal Year End: | December |
| Full Time Employees: | 89 |